Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-TNF treatment in rheumatoid arthritis.

Current pharmaceutical design - 1 Jan 2011

Geiler Janina, Buch Maya, McDermott Michael F

Abstract excerpt

Rheumatoid arthritis (RA), the most common autoimmune disease, is characterized by persistent synovitis and systemic inflammation. Genetic predisposition as well as autoantibodies and environmental factors, such as smoking, are associated with an increased risk of RA. Traditionally RA has been treated with disease modifying anti-rheumatic drugs (DMARDs) but in the last 15 years or so the introduction of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Rheumatoid
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome-Wide Association Study

Share to Immunologic Factors

Share to Pregnancy

Share to Remission Induction

Share to Tumor Necrosis Factor-alpha

Source

Identifiers

PMID: 21864263
DOI: 10.2174/138161211798157658

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-TNF treatment in rheumatoid arthritis.PMID 21864263Read ↗

Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy.Semantic proximity Read ↗

Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.Semantic proximity Read ↗

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 TreatmentSemantic proximity Read ↗

Targeting TNF superfamily members for therapeutic intervention in rheumatoid arthritisSemantic proximity Read ↗

Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?Semantic proximity Read ↗

COVID-19 in patients with rheumatological diseases treated with anti-TNFSemantic proximity Read ↗

Treatment of rheumatoid arthritis: new therapeutic approaches with biological agents.Semantic proximity Read ↗

Modern Pharmacologic Management of Rheumatoid Arthritis: From Methotrexate to Targeted TherapiesSemantic proximity Read ↗

Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis.Semantic proximity Read ↗

Frontiers in Rheumatoid Arthritis: Emerging Research and Unmet Needs in Pharmacologic ManagementSemantic proximity Read ↗

Genetic and Genomic Markers of Anti-TNF Treatment Response in Rheumatoid ArthritisSemantic proximity Read ↗

Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.